1-5 of 5
Lucy Lee
Close
Sort by
Journal Articles

Quality of Life in Emicizumab-Treated People with Hemophilia A in the ATHN 7 Hemophilia Natural History Study - an Assessment of Baseline PROMIS®-29 Scores

Tyler W. Buckner, Nabil Daoud, Lucy Lee, Elise Lim, Jonathan Schwartz, Karina Raimundo, Michael Recht
Journal: Blood
Blood (2023) 142 (Supplement 1): 3998.
https://doi.org/10.1182/blood-2023-174092
Published: 2023
Journal Articles

Emicizumab and Females with Hemophilia A: Case Series from ATHN 7

Michael Recht, Nabil Daoud, Lucy Lee, Paul Morton, Leslie J. Raffini
Journal: Blood
Blood (2022) 140 (Supplement 1): 2745–2746.
https://doi.org/10.1182/blood-2022-157754
Published: 2022
Journal Articles

Real-World Persistence with and Adherence to Emicizumab Prophylaxis in Persons with Hemophilia a: A Secondary Claims Database Analysis

Arash Mahajerin, Rahul Khairnar, Craig S. Meyer, Ibrahim M. Abbass, Rongrong Wang, Lucy Lee, Eunice Tzeng, Karina Raimundo
Journal: Blood
Blood (2020) 136 (Supplement 1): 13.
https://doi.org/10.1182/blood-2020-137632
Published: 2020
Journal Articles

A Phase IV, Multicenter, Open-Label Study of Emicizumab Prophylaxis in Persons with Hemophilia a with or without FVIII Inhibitors Undergoing Minor Surgical Procedures

Miguel A. Escobar, MD, Amy Dunn, Doris Quon, MD PhD, Ben Trzaskoma, Lucy Lee, Richard H Ko, Shannon L Carpenter, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-134906
Published: 2020
Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath
Journal: Blood
Blood (2019) 134 (Supplement_1): 2395.
https://doi.org/10.1182/blood-2019-123654
Published: 2019